"rationale","description","label","id","uuid:ID","name","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign_1","bc914b1c-bc5c-456c-bbc6-65eef5e14de5","Study Design 1","StudyDesign"
